



Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 14 December 2020.

I am pleased to confirm the following.

Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs: (June to November 2020)

•	Juluca (rilpivirine/dolutegravir)	4 patients
•	Dovato (lamivudine/dolutegravir)	44 patients
•	Triumeq (abacavir/lamivudine/dolutegravir)	137 patients
•	Tivicay (dolutegravir)	59 patients
•	Isentress (raltegravir)	12 patients
•	Biktarvy (TAF/emtricitabine/bictegravir)	12 patients
•	Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)	9 patients
•	Symtuza (TAF/emtricitabine/darunavir/cobisistat)	22 patients
•	Odefsey (TAF/emtricitabine/rilpivirine)	21 patients
•	Descovy (TAF/emtricitabine)	7 patients
•	Truvada or generic TDF/emtricitabine	71 patients

Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):

•	for the latest 6-month period	633 patients (June to November 2020)
•	for the Crearthe frame, July December 2010	C10 metionsta

• for the 6 months from July-December 2019 619 patients

Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:

- HIV treatment 71 patients
- Pre-exposure prophylaxis (PrEP) 0 patients (We don't provide pre-exposure prophylaxis)

Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6month period for:

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

- HIV treatment 363 packs
- Pre-exposure prophylaxis (PrEP) 0 packs

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.